• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
  • Donate
  • Contact
  • Show SearchSearch

Depot Medroxyprogesterone Acetate (Depo Provera®)

December 1, 2023

Selected References:

  • Baheiraei A, et al. 2001. Effects of progestogen-only contraceptives on breast-feeding and infant growth Int J Gynaecol Obstet, 74; 203–205
  • Borgatta L, et al. 2002. Pregnancies diagnosed during Depo- Provera use. Contraception. Sep;66(3):169-72.
  • Callahan R et al. 2015. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: A systemic review. Contraception 92(6):514-22.
  • Dahlberg K. 1982. Some effects of depotmedroxyprogesterone acetate (DMPA): Observations in the nursing infant and in the long-term user. Int J Gynaecol Obstet 20:43-48.
  • Deshmukh P, Antell K, Brown EJ. 2017. Contraception Update: Progestin-Only Implants and Injections. FP Essent.. 462:25-29.
  • Gray RH and Pardthaisong T. 1991. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 134:795-803.
  • Gray RH, Pardthaisong T. 1991. In utero exposure to steroid contraceptives and survival during infancy. Am J Epidemiol; 134:804-811.
  • Gu YQ, et al. 2004. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab. 89(5):2254-62.
  • Hogue CJ. 1991. Invited commentary: the contraceptive technology tightrope. Am J Epidemiol 134: 812-815; author response 816-817.
  • Jaffe B et al. 1990. Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate. Paediatr Perinat Epidemiol 4:184-95.
  • Jimenez J et al. 1984. Long-term follow-up of children breast-fed by mothers receiving depotmedroxyprogesterone acetate. Contraception 30:523-533.
  • Koetsawang S, et al. 1982. Transfer of contraceptive steroids in milk of women using long-acting gestagens. Contraception 25:321- 331.
  • Pardthaisong T, et al. 1992. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45:313-24.
  • Pardthaisong T, Gray R. 1988. Steroid contraceptive use and pregnancy outcome. Teratology 38:51-58
  • PDR Entry for: Depo-Provera Contraceptive Injection. 2016. Pharmacia and Upjohn Company LLC.
  • Phillips SJ, et al. 2016. Progestogen-only contraceptive use among breastfeeding women: A systematic review. Contraception; 94:226-52.
  • Ratchanon S and Taneepanichskul S. 2000. Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. Obstetrics & Gynecology 96(6):926-8.
  • Saxena BN et al. 1977. Levels of contraceptive steroids in breast milk and plasma of lactating women. Contraception 16:605-613.
  • Virutamasen P et al. 1996. Pharmacodynamic effects of depot-lprogesterone acetate (DMPA) administered to lactating women on their male infants. Contraception 54:153-157.
  • World Health Organization. 2016. Resource chart medical eligibility contraceptives – FHI 360. (n.d.). https://www.fhi360.org/sites/default/files/media/documents/resource-chart-medical-eligibility-contraceptives-english.pdf.
  • Yovich JL, et al. 1988. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 38:135-144.

 

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.